Ulrich Kunzendorf

Title: Ulrich Kunzendorf: Innovator in Anti-Apoptotic Fusion Proteins

Introduction

Ulrich Kunzendorf is a notable inventor based in Kiel, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of anti-apoptotic fusion proteins. With a total of 2 patents, his work focuses on innovative solutions for medical applications.

Latest Patents

Kunzendorf's latest patents include the invention of TAT-CrmA anti-apoptotic fusion proteins. This invention relates to a fusion protein that comprises a protein transduction domain capable of introducing the fusion protein into a mammalian cell. It also includes an anti-apoptotic protein that comprises the amino acid sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention further encompasses a pharmaceutical composition that includes such a fusion protein, particularly for blocking apoptosis in patients in need. Additionally, it provides a polynucleotide encoding the fusion protein, an expression vector containing the polynucleotide, and a host cell comprising the expression vector. Another significant patent involves anti-apoptotic fusion proteins for reducing myocardial infarction size, which shares similar characteristics and applications as the previous invention.

Career Highlights

Throughout his career, Ulrich Kunzendorf has worked with various companies, including Unipeak Consulting Sdn Bhd. His expertise in the field has allowed him to contribute to advancements in medical biotechnology.

Collaborations

Kunzendorf has collaborated with notable professionals, including his coworker Stefan Krautwald. Their joint efforts have furthered research and development in the area of anti-apoptotic therapies.

Conclusion

Ulrich Kunzendorf's innovative work in anti-apoptotic fusion proteins has the potential to significantly impact medical treatments. His patents reflect a commitment to advancing biotechnology for therapeutic purposes.